David A. Siegel Century Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 857,600 shares of IPSC stock, worth $403,072. This represents 0.0% of its overall portfolio holdings.
Number of Shares
857,600
Previous 367,100
133.61%
Holding current value
$403,072
Previous $205,000
108.78%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding IPSC
# of Institutions
56Shares Held
22.5MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA3.54MShares$1.66 Million0.57% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$1.36 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.59MShares$1.22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.1MShares$988,8180.0% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA1.7MShares$800,9890.23% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $27.7M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...